![]() Bromisoval structure
|
Common Name | Bromisoval | ||
---|---|---|---|---|
CAS Number | 496-67-3 | Molecular Weight | 223.06800 | |
Density | 1.504g/cm3 | Boiling Point | N/A | |
Molecular Formula | C6H11BrN2O2 | Melting Point | 152 °C | |
MSDS | N/A | Flash Point | N/A |
Purity | Quantity | Budget | Inquiry |
---|
Use of BromisovalBromisoval has anti-inflammatory effects and has been used as an old sedative and hypnotic. |
Name | 2-bromo-N-carbamoyl-3-methylbutanamide |
---|---|
Synonym | More Synonyms |
Description | Bromisoval has anti-inflammatory effects and has been used as an old sedative and hypnotic. |
---|---|
Related Catalog | |
In Vitro | Bromisoval (BU) suppresses nitric oxide (NO) releasing and proinflammatory cytokine expression in lipopolysaccharide (LPS)-treat BV2 cells, a murine microglial cell line. Bromisoval suppresses LPS-inducing phosphorylation of signal transducer and activator of transcription 1 (STAT1) and expression of interferon regulatory factor 1 (IRF1). The Janus kinase 1 (JAK1) inhibitor filgotinib suppresses the NO release much more weakly than that of Bromisoval, although filgotinib almost completely prevents LPS-inducing STAT1 phosphorylation. Knockdown of JAK1, STAT1, or IRF1 does not affect the suppressive effects of Bromisoval on LPS-inducing NO. A combination of Bromisoval and filgotinib synergistically suppress the NO releasing. The mitochondrial complex I inhibitor rotenone, which does not prevent STAT1 phosphorylation or IRF1 expression, suppresses proinflammatory mediator expression less significantly than Bromisoval. Bromisoval and rotenone reduce intracellular ATP (iATP) levels to a similar extent. A combination of rotenone and filgotinib suppress NO release in LPS-treated BV2 cells as strongly as Bromisoval[1]. |
In Vivo | Bromisoval (Bromvaletone) and carbromal are the most potent central depressants within each series. Depressant activities (ISD50 values) and acute toxicities (LD50 values) in male mice after intraperitoneal injection of Bromisoval are 0.35 (0.30-0.39) and 3.25 (2.89-3.62) mmol/kg, respectively[2]. |
Kinase Assay | Conditioning media are obtained from BV2 cell cultures that have been incubated for 24 h in E2 medium containing 1 μg/ml LPS, with or without Bromisoval (BU) (1-100 μg/mL) or other agents, and subjected to NO determination. To normalize the releasing NO level by the cellular protein contents, cells are solubilized with RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 0.5% w/v sodium deoxycholate, 0.1% w/v sodium dodecyl sulfate, 1.0% w/v NP-40 substitute) and the protein contents are determined by BCA protein assay reagents[1]. |
Cell Assay | Murine microglial cell line BV2 is used. BV2 cells are maintained in medium supplemented with 10% fetal bovine serum. BV2 cells are seeded onto wells in 4-well culture plates and incubated with LPS for 30 min to 24 h. When the effects of Bromisoval (BU) or other agents are investigated, BV2 cells are incubated with the appropriate agent (e.g. Bromisoval) for 30 min before the addition of LPS[1]. |
Animal Admin | Suspensions of the compounds (including Bromisoval ) in aqueous 0.5% carboxymethyl cellulose are administered intraperitoneally to adult male albino mice weighing 25-35 g. All tests are performed on groups of ten mice[2]. |
References |
Density | 1.504g/cm3 |
---|---|
Melting Point | 152 °C |
Molecular Formula | C6H11BrN2O2 |
Molecular Weight | 223.06800 |
Exact Mass | 222.00000 |
PSA | 72.19000 |
LogP | 1.69200 |
Index of Refraction | 1.514 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Safety Phrases | S24/25 |
---|---|
RTECS | YS3150000 |
HS Code | 2924210090 |
~% Bromisoval CAS#:496-67-3 |
Literature: Knoll and Co. Patent: DE275200 ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 11, p. 938 |
~% Bromisoval CAS#:496-67-3 |
Literature: Bayer and Co. Patent: DE277466 ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 12, p. 701 |
~% Bromisoval CAS#:496-67-3 |
Literature: Fourneau; Florence Bulletin de la Societe Chimique de France, 1927 , vol. <4>41, p. 1525 Full Text Show Details Knoll and Co. Patent: DE185962 ; |
~% Bromisoval CAS#:496-67-3 |
Literature: Knoll and Co. Patent: DE185962 ; |
~% Bromisoval CAS#:496-67-3 |
Literature: Bayer and Co. Patent: DE277466 ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 12, p. 701 |
HS Code | 2924210090 |
---|---|
Summary | 2924210090 other ureines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
Alural |
EINECS 207-825-7 |
Bromaral |
Bromural |
Alluval |
Bromoxil |
1-(2-Bromoisovaleryl)urea |
Abroval |
Bromisoval |
bromisovalum |
Bromovalerylurea |
B.V.U. |
Bromoval |
Bromyl |
MFCD00047873 |
2-Bromo-3-methylbutyrylurea |
bromvalerylurea |